Table Info

Table 1.

List of information on LDHA inhibitors

LDHA inhibitors	Competitive sites	LDHA (K_i value)	Shortcomings	References
Oxamate	Pyruvate	136.3 μM	High polarity, low exocytosis across cell membranes, high dosing concentration	[71–75]
(R)-(–)-gossypol	NADH	1.9 μM	Non-specific toxicity	[76–78, 84, 85]
FX11	NADH	8 μM	Not yet used in clinical trials	[76, 78]
Quinoline 3-sulfonamides	NADH	4–6 nM	Low clearance in vivo	[88]
GF	Pyruvate	5.46 μM	Possible inhibition of RNA synthesis rather than blockage of glycolysis	[89, 92]
GF	NADH	56 μM		[89, 92]
NHI	Pyruvate, NADH	8.9 μM	Novel inhibitors to be studied	[15, 93]
GNE-140	NADH	-	Novel inhibitors to be studied	[96]

GF: galloflavin. K_i: inhibition constant; -: no literature has demonstrated it

Declarations

Author contributions

WX, XL, and YZ: Writing—original draft. MZ and ML: Writing—review & editing, Supervision.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work is supported by the National Natural Science Foundation of China [81960519, 81660463, 82060514], the Natural Science Foundation of Hainan Province [2019CXTD406], and Hainan Province Science and Technology Special Fund [ZDYF2021SHFZ222]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. [DOI] [PubMed]

Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519–30. [DOI] [PubMed] [PMC]

Cori CF, Cori GT. The carbohydrate metabolism of tumors. J Biol Chem. 1925;64:11–2.

Warburg O. On the origin of cancer cells. Science. 1956;123:309–14. [DOI] [PubMed]

Vlashi E, Lagadec C, Vergnes L, Reue K, Frohnen P, Chan M, et al. Metabolic differences in breast cancer stem cells and differentiated progeny. Breast Cancer Res Treat. 2014;146:525–34. [DOI] [PubMed] [PMC]

Wenger KJ, Steinbach JP, Bähr O, Pilatus U, Hattingen E. Lower lactate levels and lower intracellular pH in patients with IDH-mutant versus wild-type gliomas. AJNR Am J Neuroradiol. 2020;41:1414–22. [DOI] [PubMed] [PMC]

Brown TP, Ganapathy V. Lactate/GPR81 signaling and proton motive force in cancer: role in angiogenesis, immune escape, nutrition, and Warburg phenomenon. Pharmacol Ther. 2020;206:107451. [DOI] [PubMed]

Hayes C, Donohoe CL, Davern M, Donlon NE. The oncogenic and clinical implications of lactate induced immunosuppression in the tumour microenvironment. Cancer Lett. 2021;500:75–86. [DOI] [PubMed]

Kanno T, Sudo K, Maekawa M, Nishimura Y, Ukita M, Fukutake K. Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy. Clin Chim Acta. 1988;173:89–98. [DOI] [PubMed]

10.

Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017;168:657–69. [DOI] [PubMed] [PMC]

11.

Murgai M, Ju W, Eason M, Kline J, Beury DW, Kaczanowska S, et al. KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis. Nat Med. 2017;23:1176–90. [DOI] [PubMed] [PMC]

12.

Cheng CS, Tan HY, Wang N, Chen L, Meng Z, Chen Z, et al. Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression. Clin Transl Med. 2021;11:e467. [DOI] [PubMed] [PMC]

13.

Fang Y, Liu W, Tang Z, Ji X, Zhou Y, Song S, et al. Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack. Hepatology. 2023;77:109–23. [DOI] [PubMed]

14.

Miranda-Gonçalves V, Honavar M, Pinheiro C, Martinho O, Pires MM, Pinheiro C, et al. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol. 2013;15:172–88. [DOI] [PubMed] [PMC]

15.

Granchi C, Roy S, Giacomelli C, Macchia M, Tuccinardi T, Martinelli A, et al. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J Med Chem. 2011;54:1599–612. [DOI] [PubMed]

16.

Curtis NJ, Mooney L, Hopcroft L, Michopoulos F, Whalley N, Zhong H, et al. Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity. Oncotarget. 2017;8:69219–36. [DOI] [PubMed] [PMC]

17.

Warburg O. The metabolism of carcinoma cells. J Cancer Res. 1925;9:148–63.

18.

Heneberg P. Lactic acidosis in patients with solid cancer. Antioxid Redox Signal. 2022;37:1130–52. [DOI] [PubMed]

19.

Sillos EM, Shenep JL, Burghen GA, Pui CH, Behm FG, Sandlund JT. Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature. Cancer. 2001;92:2237–46. [DOI] [PubMed]

20.

Ariceta G, Barrios K, Brown BD, Hoppe B, Rosskamp R, Langman CB. Hepatic lactate dehydrogenase A: an RNA interference target for the treatment of all known types of primary hyperoxaluria. Kidney Int Rep. 2021;6:1088–98. [DOI] [PubMed] [PMC]

21.

Forkasiewicz A, Dorociak M, Stach K, Szelachowski P, Tabola R, Augoff K. The usefulness of lactate dehydrogenase measurements in current oncological practice. Cell Mol Biol Lett. 2020;25:35. [DOI] [PubMed] [PMC]

22.

Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010;107:2037–42. [DOI] [PubMed] [PMC]

23.

Li S, Gao J, Zhuang X, Zhao C, Hou X, Xing X, et al. Cyclin G2 Inhibits the Warburg effect and tumour progression by suppressing LDHA phosphorylation in glioma. Int J Biol Sci. 2019;15:544–55. [DOI] [PubMed] [PMC]

24.

Miao P, Sheng S, Sun X, Liu J, Huang G. Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapy. IUBMB Life. 2013;65:904–10. [DOI] [PubMed]

25.

Wang C, Li Y, Yan S, Wang H, Shao X, Xiao M, et al. Interactome analysis reveals that lncRNA HULC promotes aerobic glycolysis through LDHA and PKM2. Nat Commun. 2020;11:3162. [DOI] [PubMed] [PMC]

26.

Liu Y, Guo JZ, Liu Y, Wang K, Ding W, Wang H, et al. Nuclear lactate dehydrogenase A senses ROS to produce α-hydroxybutyrate for HPV-induced cervical tumor growth. Nat Commun. 2018;9:4429. [DOI] [PubMed] [PMC]

27.

Han J, Chen X, Wang J, Liu B. Glycolysis-related lncRNA TMEM105 upregulates LDHA to facilitate breast cancer liver metastasis via sponging miR-1208. Cell Death Dis. 2023;14:80. [DOI] [PubMed] [PMC]

28.

Martínez-Ordoñez A, Seoane S, Avila L, Eiro N, Macía M, Arias E, et al. POU1F1 transcription factor induces metabolic reprogramming and breast cancer progression via LDHA regulation. Oncogene. 2021;40:2725–40. [DOI] [PubMed] [PMC]

29.

An J, Zhang Y, He J, Zang Z, Zhou Z, Pei X, et al. Lactate dehydrogenase A promotes the invasion and proliferation of pituitary adenoma. Sci Rep. 2017;7:4734. [DOI] [PubMed] [PMC]

30.

Yang Y, Chong Y, Chen M, Dai W, Zhou X, Ji Y, et al. Targeting lactate dehydrogenase a improves radiotherapy efficacy in non-small cell lung cancer: from bedside to bench. J Transl Med. 2021;19:170. [DOI] [PubMed] [PMC]

31.

Dhup S, Dadhich RK, Porporato PE, Sonveaux P. Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr Pharm Des. 2012;18:1319–30. [DOI] [PubMed]

32.

Zhao J, Tian Z, Zhao S, Feng D, Guo Z, Wen L, et al. Insights into the effect of catalytic intratumoral lactate depletion on metabolic reprogramming and immune activation for antitumoral activity. Adv Sci (Weinh). 2023;10:e2204808. [DOI] [PubMed] [PMC]

33.

Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res. 2011;71:6921–5. [DOI] [PubMed]

34.

Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33. [DOI] [PubMed] [PMC]

35.

Locasale JW, Cantley LC. Metabolic flux and the regulation of mammalian cell growth. Cell Metab. 2011;14:443–51. [DOI] [PubMed] [PMC]

36.

Pfeiffer T, Schuster S, Bonhoeffer S. Cooperation and competition in the evolution of ATP-producing pathways. Science. 2001;292:504–7. [DOI] [PubMed]

37.

Felmlee MA, Jones RS, Rodriguez-Cruz V, Follman KE, Morris ME. Monocarboxylate transporters (SLC16): function, regulation, and role in health and disease. Pharmacol Rev. 2020;72:466–85. [DOI] [PubMed] [PMC]

38.

Barnes EME, Xu Y, Benito A, Herendi L, Siskos AP, Aboagye EO, et al. Lactic acidosis induces resistance to the pan-Akt inhibitor uprosertib in colon cancer cells. Br J Cancer. 2020;122:1298–308. [DOI] [PubMed] [PMC]

39.

Végran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Res. 2011;71:2550–60. [DOI] [PubMed]

40.

Zhang YX, Zhao YY, Shen J, Sun X, Liu Y, Liu H, et al. Nanoenabled modulation of acidic tumor microenvironment reverses anergy of infiltrating T cells and potentiates anti-PD-1 therapy. Nano Lett. 2019;19:2774–83. [DOI] [PubMed]

41.

Hanson DJ, Nakamura S, Amachi R, Hiasa M, Oda A, Tsuji D, et al. Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation. Oncotarget. 2015;6:33568–86. [DOI] [PubMed] [PMC]

42.

Ahmed K, Tunaru S, Tang C, Müller M, Gille A, Sassmann A, et al. An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81. Cell Metab. 2010;11:311–9. [DOI] [PubMed]

43.

Ahmed K, Tunaru S, Offermanns S. GPR109A, GPR109B and GPR81, a family of hydroxy-carboxylic acid receptors. Trends Pharmacol Sci. 2009;30:557–62. [DOI] [PubMed]

44.

Rooney K, Trayhurn P. Lactate and the GPR81 receptor in metabolic regulation: implications for adipose tissue function and fatty acid utilisation by muscle during exercise. Br J Nutr. 2011;106:1310–6. [DOI] [PubMed]

45.

Hoque R, Farooq A, Ghani A, Gorelick F, Mehal WZ. Lactate reduces liver and pancreatic injury in toll-like receptor– and inflammasome-mediated inflammation via GPR81-mediated suppression of innate immunity. Gastroenterology. 2014;146:1763–74. [DOI] [PubMed] [PMC]

46.

Roland CL, Arumugam T, Deng D, Liu SH, Philip B, Gomez S, et al. Cell surface lactate receptor GPR81 is crucial for cancer cell survival. Cancer Res. 2014;74:5301–10. [DOI] [PubMed] [PMC]

47.

Longhitano L, Forte S, Orlando L, Grasso S, Barbato A, Vicario N, et al. The crosstalk between GPR81/IGFBP6 promotes breast cancer progression by modulating lactate metabolism and oxidative stress. Antioxidants (Basel). 2022;11:275. [DOI] [PubMed] [PMC]

48.

Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453–8. [DOI] [PubMed]

49.

Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell. 2006;127:679–95. [DOI] [PubMed]

50.

Gandalovičová A, Rosel D, Fernandes M, Veselý P, Heneberg P, Čermák V, et al. Migrastatics-anti-metastatic and anti-invasion drugs: promises and challenges. Trends Cancer. 2017;3:391–406. [DOI] [PubMed] [PMC]

51.

Chen P, Zuo H, Xiong H, Kolar MJ, Chu Q, Saghatelian A, et al. Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. Proc Natl Acad Sci U S A. 2017;114:580–5. [DOI] [PubMed] [PMC]

52.

Bergers G, Fendt SM. The metabolism of cancer cells during metastasis. Nat Rev Cancer. 2021;21:162–80. [DOI] [PubMed] [PMC]

53.

Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, et al.; Tumour and Angiogenesis Research Group. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 2003;89:877–85. [DOI] [PubMed] [PMC]

54.

Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Trarbach T, Folprecht G, et al. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res. 2011;17:4892–900. [DOI] [PubMed] [PMC]

55.

Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res. 2002;8:1284–91. [PubMed]

56.

Payen VL, Mina E, Van Hée VF, Porporato PE, Sonveaux P. Monocarboxylate transporters in cancer. Mol Metab. 2020;33:48–66. [DOI] [PubMed] [PMC]

57.

Voss DM, Spina R, Carter DL, Lim KS, Jeffery CJ, Bar EE. Disruption of the monocarboxylate transporter-4-basigin interaction inhibits the hypoxic response, proliferation, and tumor progression. Sci Rep. 2017;7:4292. [DOI] [PubMed] [PMC]

58.

Chang H, Xu Q, Li J, Li M, Zhang Z, Ma H, et al. Lactate secreted by PKM2 upregulation promotes Galectin-9-mediated immunosuppression via inhibiting NF-κB pathway in HNSCC. Cell Death Dis. 2021;12:725. [DOI] [PubMed] [PMC]

59.

Pan S, Hu Y, Hu M, Xu Y, Chen M, Du C, et al. S100A8 facilitates cholangiocarcinoma metastasis via upregulation of VEGF through TLR4/NF-κB pathway activation. Int J Oncol. 2020;56:101–12. [DOI] [PubMed] [PMC]

60.

Rattigan YI, Patel BB, Ackerstaff E, Sukenick G, Koutcher JA, Glod JW, et al. Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment. Exp Cell Res. 2012;318:326–35. [DOI] [PubMed] [PMC]

61.

Gillies RJ, Gatenby RA. Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr. 2007;39:251–7. [DOI] [PubMed]

62.

Pértega-Gomes N, Vizcaíno JR, Attig J, Jurmeister S, Lopes C, Baltazar F. A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer. 2014;14:352. [DOI] [PubMed] [PMC]

63.

Gu Y, Ji F, Liu N, Zhao Y, Wei X, Hu S, et al. Loss of miR-192-5p initiates a hyperglycolysis and stemness positive feedback in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39:268. [DOI] [PubMed] [PMC]

64.

Ji Y, Yang C, Tang Z, Yang Y, Tian Y, Yao H, et al. Adenylate kinase hCINAP determines self-renewal of colorectal cancer stem cells by facilitating LDHA phosphorylation. Nat Commun. 2017;8:15308. [DOI] [PubMed] [PMC]

65.

Song K, Kwon H, Han C, Zhang J, Dash S, Lim K, et al. Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by miR-122. Oncotarget. 2015;6:40822–35. [DOI] [PubMed] [PMC]

66.

Daniele S, Giacomelli C, Zappelli E, Granchi C, Trincavelli ML, Minutolo F, et al. Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death. Sci Rep. 2015;5:15556. [DOI] [PubMed] [PMC]

67.

Nakashima C, Kirita T, Yamamoto K, Mori S, Luo Y, Sasaki T, et al. Malic enzyme 1 is associated with tumor budding in oral squamous cell carcinomas. Int J Mol Sci. 2020;21:7149. [DOI] [PubMed] [PMC]

68.

Li X, Zhang Z, Zhang Y, Cao Y, Wei H, Wu Z. Upregulation of lactate-inducible snail protein suppresses oncogene-mediated senescence through p16^INK4a inactivation. J Exp Clin Cancer Res. 2018;37:39. [DOI] [PubMed] [PMC]

69.

Hou X, Shi X, Zhang W, Li D, Hu L, Yang J, et al. LDHA induces EMT gene transcription and regulates autophagy to promote the metastasis and tumorigenesis of papillary thyroid carcinoma. Cell Death Dis. 2021;12:347. [DOI] [PubMed] [PMC]

70.

Liu M, Quek LE, Sultani G, Turner N. Epithelial-mesenchymal transition induction is associated with augmented glucose uptake and lactate production in pancreatic ductal adenocarcinoma. Cancer Metab. 2016;4:19. [DOI] [PubMed] [PMC]

71.

Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A, et al. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res. 2008;10:R84. [DOI] [PubMed] [PMC]

72.

Zhai X, Yang Y, Wan J, Zhu R, Wu Y. Inhibition of LDH-A by oxamate induces G2/M arrest, apoptosis and increases radiosensitivity in nasopharyngeal carcinoma cells. Oncol Rep. 2013;30:2983–91. [DOI] [PubMed]

73.

Valvona CJ, Fillmore HL. Oxamate, but not selective targeting of LDH-A, inhibits medulloblastoma cell glycolysis, growth and motility. Brain Sci. 2018;8:56. [DOI] [PubMed] [PMC]

74.

Li X, Lu W, Hu Y, Wen S, Qian C, Wu W, et al. Effective inhibition of nasopharyngeal carcinoma in vitro and in vivo by targeting glycolysis with oxamate. Int J Oncol. 2013;43:1710–8. [DOI] [PubMed]

75.

Altinoz MA, Ozpinar A. Oxamate targeting aggressive cancers with special emphasis to brain tumors. Biomed Pharmacother. 2022;147:112686. [DOI] [PubMed]

76.

Granchi C, Paterni I, Rani R, Minutolo F. Small-molecule inhibitors of human LDH5. Future Med Chem. 2013;5:1967–91. [DOI] [PubMed] [PMC]

77.

Burgos C, Gerez de Burgos NM, Rovai LE, Blanco A. In vitro inhibition by gossypol of oxidoreductases from human tissues. Biochem Pharmacol. 1986;35:801–4. [DOI] [PubMed]

78.

Yu Y, Deck JA, Hunsaker LA, Deck LM, Royer RE, Goldberg E, et al. Selective active site inhibitors of human lactate dehydrogenases A4, B4, and C4. Biochem Pharmacol. 2001;62:81–9. [DOI] [PubMed]

79.

Gilbert NE, O’Reilly JE, Chang CJ, Lin YC, Brueggemeier RW. Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci. 1995;57:61–7. [DOI] [PubMed]

80.

Tuszynski GP, Cossu G. Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. Cancer Res. 1984;44:768–71. [PubMed]

81.

Shelley MD, Hartley L, Fish RG, Groundwater P, Morgan JJ, Mort D, et al. Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines. Cancer Lett. 1999;135:171–80. [DOI] [PubMed]

82.

Coyle T, Levante S, Shetler M, Winfield J. In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines. J Neurooncol. 1994;19:25–35. [DOI] [PubMed]

83.

Wu YW, Chik CL, Knazek RA. An in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenocortical carcinoma. Cancer Res. 1989;49:3754–8. [PubMed]

84.

Qian SZ, Jing GW, Wu XY, Xu Y, Li YQ, Zhou ZH. Gossypol related hypokalemia. Clinicopharmacologic studies. Chin Med J (Engl). 1980;93:477–82. [PubMed]

85.

Yu ZH, Chan HC. Gossypol as a male antifertility agent – why studies should have been continued. Int J Androl. 1998;21:2–7. [DOI] [PubMed]

86.

Xian ZY, Liu JM, Chen QK, Chen HZ, Ye CJ, Xue J, et al. Inhibition of LDHA suppresses tumor progression in prostate cancer. Tumour Biol. 2015;36:8093–100. [DOI] [PubMed] [PMC]

87.

Rellinger EJ, Craig BT, Alvarez AL, Dusek HL, Kim KW, Qiao J, et al. FX11 inhibits aerobic glycolysis and growth of neuroblastoma cells. Surgery. 2017;161:747–52. [DOI] [PubMed] [PMC]

88.

Billiard J, Dennison JB, Briand J, Annan RS, Chai D, Colón M, et al. Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer Metab. 2013;1:19. [DOI] [PubMed] [PMC]

89.

Manerba M, Vettraino M, Fiume L, Di Stefano G, Sartini A, Giacomini E, et al. Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase. ChemMedChem. 2012;7:311–7. [DOI] [PubMed]

90.

Han X, Sheng X, Jones HM, Jackson AL, Kilgore J, Stine JE, et al. Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells. J Hematol Oncol. 2015;8:2. [DOI] [PubMed] [PMC]

91.

Rahnasto-Rilla M, Järvenpää J, Huovinen M, Schroderus AM, Ihantola EL, Küblbeck J, et al. Effects of galloflavin and ellagic acid on sirtuin 6 and its anti-tumorigenic activities. Biomed Pharmacother. 2020;131:110701. [DOI] [PubMed]

92.

Fiume L, Vettraino M, Carnicelli D, Arfilli V, Di Stefano G, Brigotti M. Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells. Biochem Biophys Res Commun. 2013;430:466–9. [DOI] [PubMed]

93.

Granchi C, Calvaresi EC, Tuccinardi T, Paterni I, Macchia M, Martinelli A, et al. Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds. Org Biomol Chem. 2013;11:6588–96. [DOI] [PubMed] [PMC]

94.

Di Bussolo V, Calvaresi EC, Granchi C, Del Bino L, Frau I, Lang MC, et al. Synthesis and biological evaluation of non-glucose glycoconjugate N-hydroyxindole class LDH inhibitors as anticancer agents. RSC Adv. 2015;5:19944–54. [DOI] [PubMed] [PMC]

95.

El Hassouni B, Franczak M, Capula M, Vonk CM, Gomez VM, Smolenski RT, et al. Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction. Oncoscience. 2020;7:76–80. [DOI] [PubMed] [PMC]

96.

Boudreau A, Purkey HE, Hitz A, Robarge K, Peterson D, Labadie S, et al. Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. Nat Chem Biol. 2016;12:779–86. [DOI] [PubMed]

97.

Mazzio E, Mack N, Badisa RB, Soliman KFA. Triple isozyme lactic acid dehydrogenase inhibition in fully viable MDA-MB-231 cells induces cytostatic effects that are not reversed by exogenous lactic acid. Biomolecules. 2021;11:1751. [DOI] [PubMed] [PMC]

98.

Kong SC, Nøhr-Nielsen A, Zeeberg K, Reshkin SJ, Hoffmann EK, Novak I, et al. Monocarboxylate transporters MCT1 and MCT4 regulate migration and invasion of pancreatic ductal adenocarcinoma cells. Pancreas. 2016;45:1036–47. [DOI] [PubMed]

99.

Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, Philp NJ, Lin Z, Gandara R, et al. Using the “reverse Warburg effect” to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle. 2012;11:1108–17. [DOI] [PubMed] [PMC]

100.

Floridi A, Paggi MG, D’Atri S, De Martino C, Marcante ML, Silvestrini B, et al. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res. 1981;41:4661–6. [PubMed]

101.

Nath K, Guo L, Nancolas B, Nelson DS, Shestov AA, Lee SC, et al. Mechanism of antineoplastic activity of lonidamine. Biochim Biophys Acta. 2016;1866:151–62. [DOI] [PubMed] [PMC]

102.

Nancolas B, Guo L, Zhou R, Nath K, Nelson DS, Leeper DB, et al. The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. Biochem J. 2016;473:929–36. [DOI] [PubMed] [PMC]

103.

Wang Q, Morris ME. Flavonoids modulate monocarboxylate transporter-1-mediated transport of γ-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos. 2007;35:201–8. [DOI] [PubMed]

104.

Sirvent P, Bordenave S, Vermaelen M, Roels B, Vassort G, Mercier J, et al. Simvastatin induces impairment in skeletal muscle while heart is protected. Biochem Biophys Res Commun. 2005;338:1426–34. [DOI] [PubMed]

105.

Poole RC, Halestrap AP. Reversible and irreversible inhibition, by stilbenedisulphonates, of lactate transport into rat erythrocytes. Identification of some new high-affinity inhibitors. Biochem J. 1991;275:307–12. [DOI] [PubMed] [PMC]

106.

Izumi H, Takahashi M, Uramoto H, Nakayama Y, Oyama T, Wang KY, et al. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci. 2011;102:1007–13. [DOI] [PubMed]

107.

Ovens MJ, Davies AJ, Wilson MC, Murray CM, Halestrap AP. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7–10. Biochem J. 2010;425:523–30. [DOI] [PubMed] [PMC]

108.

Guan X, Bryniarski MA, Morris ME. In vitro and in vivo efficacy of the monocarboxylate transporter 1 inhibitor AR-C155858 in the murine 4T1 breast cancer tumor model. AAPS J. 2018;21:3. [DOI] [PubMed] [PMC]

109.

Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, et al. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica. 2017;102:1247–57. [DOI] [PubMed] [PMC]

110.

Guan X, Morris ME. In vitro and in vivo efficacy of AZD3965 and alpha-cyano-4-hydroxycinnamic acid in the murine 4T1 breast tumor model. AAPS J. 2020;22:84. [DOI] [PubMed] [PMC]

111.

Plummer R, Halford S, Jones P, Wedge S, Hirschberg S, Veal G, et al. A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours. Ann Oncol. 2018;29:iii9. [DOI]

112.

McNeillis R, Greystoke A, Walton J, Bacon C, Keun H, Siskos A, et al. A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965. Br J Cancer. 2020;122:1141–5. [DOI] [PubMed] [PMC]

113.

Doherty JR, Yang C, Scott KE, Cameron MD, Fallahi M, Li W, et al. Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis. Cancer Res. 2014;74:908–20. [DOI] [PubMed] [PMC]

114.

Quanz M, Bender E, Kopitz C, Grünewald S, Schlicker A, Schwede W, et al. Preclinical efficacy of the novel monocarboxylate transporter 1 inhibitor BAY-8002 and associated markers of resistance. Mol Cancer Ther. 2018;17:2285–96. [DOI] [PubMed]

115.

Futagi Y, Kobayashi M, Narumi K, Furugen A, Iseki K. Identification of a selective inhibitor of human monocarboxylate transporter 4. Biochem Biophys Res Commun. 2018;495:427–32. [DOI] [PubMed]

116.

Nadai T, Narumi K, Furugen A, Saito Y, Iseki K, Kobayashi M. Pharmacological inhibition of MCT4 reduces 4-hydroxytamoxifen sensitivity by increasing HIF-1α protein expression in ER-positive MCF-7 breast cancer cells. Biol Pharm Bull. 2021;44:1247–53. [DOI] [PubMed]

117.

Cluntun AA, Badolia R, Lettlova S, Parnell KM, Shankar TS, Diakos NA, et al. The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure. Cell Metab. 2021;33:629–48.e10. [DOI] [PubMed] [PMC]

118.

Wyatt LC, Lewis JS, Andreev OA, Reshetnyak YK, Engelman DM. Applications of pHLIP technology for cancer imaging and therapy. Trends Biotechnol. 2017;35:653–64. [DOI] [PubMed] [PMC]

119.

Moshnikova A, DuPont M, Visca H, Engelman DM, Andreev OA, Reshetnyak YK. Eradication of tumors and development of anti-cancer immunity using STINGa targeted by pHLIP. Front Oncol. 2022;12:1023959. [DOI] [PubMed] [PMC]

120.

Bola BM, Chadwick AL, Michopoulos F, Blount KG, Telfer BA, Williams KJ, et al. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther. 2014;13:2805–16. [DOI] [PubMed] [PMC]

121.

Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013;26:465–84. [DOI] [PubMed] [PMC]

122.

Ogino S, Nowak JA, Hamada T, Milner DA Jr, Nishihara R. Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. Annu Rev Pathol. 2019;14:83–103. [DOI] [PubMed] [PMC]

123.

Inamura K, Hamada T, Bullman S, Ugai T, Yachida S, Ogino S. Cancer as microenvironmental, systemic and environmental diseases: opportunity for transdisciplinary microbiomics science. Gut. 2022;71:2107–22. [DOI] [PubMed] [PMC]

124.

Galeano Niño JL, Wu H, LaCourse KD, Kempchinsky AG, Baryiames A, Barber B, et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature. 2022;611:810–7. [DOI] [PubMed] [PMC]

125.

Klement RJ, Pazienza V. Impact of different types of diet on gut microbiota profiles and cancer prevention and treatment. Medicina (Kaunas). 2019;55:84. [DOI] [PubMed] [PMC]

126.

Wang G, Yu Y, Wang YZ, Wang JJ, Guan R, Sun Y, et al. Role of SCFAs in gut microbiome and glycolysis for colorectal cancer therapy. J Cell Physiol. 2019;234:17023–49. [DOI] [PubMed]

127.

Lochhead P, Chan AT, Giovannucci E, Fuchs CS, Wu K, Nishihara R, et al. Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol. 2014;109:1205–14. [DOI] [PubMed] [PMC]

128.

Lochhead P, Chan AT, Nishihara R, Fuchs CS, Beck AH, Giovannucci E, et al. Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol. 2015;28:14–29. [DOI] [PubMed] [PMC]